We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Survival Not Impacted by Red Blood Cells Storage

By LabMedica International staff writers
Posted on 17 Oct 2013
Print article
Image: Blood Bank Refrigerator (Photo courtesy of Thermo Electron).
Image: Blood Bank Refrigerator (Photo courtesy of Thermo Electron).
The duration of storage of transfused red blood cells (RBC) has been associated with poor clinical outcomes and may influence cancer patients overall survival or recurrence.

The goal of RBC transfusion is to increase the delivery of oxygen to tissue in vulnerable patients and remains an essential component in the management of medically ill patients, but changes that occur during storage might impair oxygen delivery through a multitude of metabolic and physiologic changes that ensue.

Transfusion specialists at the Ottawa Hospital (ON, Canada) analyzed the data from 27,591 patients diagnosed with cancer between January 01, 2000 and December 31, 2005. There were 1,929 patients who had received RBC transfusions within one year from diagnosis. Transfused RBC units were categorized as "new'' if stored for less than 14 days, "intermediate'' if stored between 14 and 28 days and "old'' if stored for more than 28 days.

Overall survival was not associated with duration of storage of transfused RBC with a median survival of 1.2 years for new RBC units, 1.7 years for intermediate storage, and 1.1 years for older RBC units. The mean number of RBC transfusions was 3.42 with 55.5% of patients, receiving between one to two RBC units. Of those patients who received a RBC transfusion within one year from diagnosis, 56.8% were transfused within the first six months. Almost half of the patients requiring transfusion within the first year from diagnosis had either a gastrointestinal or lung malignancy.

Cancer recurrence, defined as recurrence of original malignancy or new metastatic disease, was significantly higher in patients who received a RBC transfusion than those who did not, but recurrence rates were not significantly influenced by the duration of storage of transfused RBC. The data from the study suggests that the duration of storage of transfused RBC has a negligible effect on overall survival (OS) of cancer patients. Not surprisingly, OS was influenced by the patient’s age, advanced stage, chemotherapy and radiation use, cancer-related surgery and cancer recurrence. Although receiving a RBC transfusion was associated with OS in univariate analysis, this was not evident when accounting for confounding variables.

The authors concluded their study highlights the inferior survival of cancer patients requiring RBC transfusions; however, there is no apparent influence of the duration of storage of transfused RBC units on OS or cancer recurrence. They concluded that current RBC transfusion policies that do not differentiate between duration of storage of RBC units are adequate for patients with underlying malignancy. The study was published on July 16, 2013, in the journal Public Library of Science ONE.

Related Links:

Ottawa Hospital


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Histamine ELISA
Histamine ELISA
New
Hepatitis B Virus Test
HBs Ab – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.